Stemline Therapeutics Inc (NASDAQ:STML) COO Kenneth Hoberman sold 1,851 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $15.67, for a total transaction of $29,005.17. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Kenneth Hoberman also recently made the following trade(s):
- On Monday, January 8th, Kenneth Hoberman sold 14,040 shares of Stemline Therapeutics stock. The shares were sold at an average price of $13.93, for a total transaction of $195,577.20.
- On Friday, December 15th, Kenneth Hoberman sold 11,943 shares of Stemline Therapeutics stock. The stock was sold at an average price of $14.18, for a total transaction of $169,351.74.
- On Monday, December 18th, Kenneth Hoberman sold 11,983 shares of Stemline Therapeutics stock. The stock was sold at an average price of $14.18, for a total transaction of $169,918.94.
Shares of Stemline Therapeutics Inc (NASDAQ:STML) traded down $0.05 during trading hours on Friday, hitting $15.90. 201,545 shares of the stock traded hands, compared to its average volume of 336,593. Stemline Therapeutics Inc has a 52-week low of $6.35 and a 52-week high of $17.40. The company has a market cap of $459.21, a PE ratio of -6.19 and a beta of -0.02.
Several large investors have recently modified their holdings of STML. Voya Investment Management LLC bought a new position in shares of Stemline Therapeutics in the 2nd quarter worth approximately $102,000. Royce & Associates LP purchased a new stake in Stemline Therapeutics in the 4th quarter worth approximately $106,000. Nationwide Fund Advisors increased its holdings in Stemline Therapeutics by 7.2% in the 2nd quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock worth $117,000 after acquiring an additional 855 shares in the last quarter. Two Sigma Investments LP purchased a new stake in Stemline Therapeutics in the 4th quarter worth approximately $170,000. Finally, Alliancebernstein L.P. purchased a new stake in Stemline Therapeutics in the 2nd quarter worth approximately $178,000. Hedge funds and other institutional investors own 42.85% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.com-unik.info/2018/02/17/stemline-therapeutics-inc-stml-coo-sells-29005-17-in-stock.html.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.